Plain-English translation of NCT07646613 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing ASY202, an inhaled powder medication designed to treat migraine attacks when they happen. You would use a handheld inhaler device to breathe in the medication during a migraine. The study wants to find out whether this treatment works well, is safe, and is tolerable for adults with migraine.
Current migraine treatments don't work equally well for everyone, and researchers want to develop new options that might be faster-acting or easier to use. This medication is being tested to see if an inhaled approach could be a helpful addition to the tools available for treating migraines.
You likely qualify if…
You likely don't qualify if…
The study lasts about 16 weeks and includes a screening visit to confirm you qualify, two treatment periods separated by at least a week, and a final safety check-up. During each treatment period, you'll use the inhaler device to treat a migraine attack, and neither you nor the study staff will know whether you're receiving the actual medication or placebo. You'll track how the treatment works and any side effects you experience.
AI-generated summary from trial data · Aug 7, 2026 · Not medical advice
United States